The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study.
Hojjat AhmadzadehfarRalf MaternRichard P BaumRobert SeifertKatharina KesselMartin BögemannClemens KratochwilHendrik RathkeHarun IlhanHanna SvirydenkaMike SathekgeLevent KabasakalAnna YordanovaFrancisco Osvaldo Garcia-PerezKalevi KairemoMasha MaharajDiana PaezIrene VirgoliniKambiz RahbarPublished in: European journal of nuclear medicine and molecular imaging (2021)
The extent of bone involvement correlated negatively with the OS after RLT; however, it showed no relevant correlation with the PSA response rate. Prior therapy with Ra-223 may have a positive impact on OS. Haematotoxicity was higher in patients with more than 20 bone lesions; nevertheless, the majority of these patients did not show a relevant haematotoxicity.
Keyphrases
- bone mineral density
- end stage renal disease
- soft tissue
- prostate cancer
- bone loss
- newly diagnosed
- ejection fraction
- bone regeneration
- chronic kidney disease
- postmenopausal women
- oxidative stress
- patient reported outcomes
- computed tomography
- pet imaging
- systemic lupus erythematosus
- mesenchymal stem cells
- ankylosing spondylitis
- patient reported